XML 167 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and other intangible assets - Additional Information (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Sep. 29, 2023
Feb. 08, 2022
Disclosure of reconciliation of changes in goodwill [line items]          
Goodwill € 43,384 € 49,404 € 49,892    
Intangible assets other than goodwill 22,629 24,319 21,640    
Gross value          
Disclosure of reconciliation of changes in goodwill [line items]          
Acquisitions and other increases 1,554 [1] 3,112 [1] 571    
Marketed products          
Disclosure of reconciliation of changes in goodwill [line items]          
Intangible assets other than goodwill 12,700 € 16,600 12,700    
Useful life, intangible assets other than goodwill (in years)   10 years      
Technological platforms          
Disclosure of reconciliation of changes in goodwill [line items]          
Intangible assets other than goodwill € 1,100 € 1,200 € 2,200    
Useful life, intangible assets other than goodwill (in years) 18 years        
QRIB Intermediate Holding          
Disclosure of reconciliation of changes in goodwill [line items]          
Identifiable intangible assets recognised as of acquisition date       € 774  
Goodwill       € 484  
Amunix [Member]          
Disclosure of reconciliation of changes in goodwill [line items]          
Identifiable intangible assets recognised as of acquisition date         € 493
Goodwill         € 609
[1] (f)This line mainly comprises:
In 2023:
–the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus
(nirsevimab) (see Note C.2.);
–an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-
commercialization of TEV’574;and
–an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against
extra-intestinal pathogenic strains of E-Coli.
In 2024:
–an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the
co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and
–an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and
commercialization rights to aficamten in China.